Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the preferred agents in the 2nd line setting of RCC once a patient has progressed on pembrolizumab/axitinib or ipilimumab/nivolumab.
